Search

Different studies in experimental diabetes models suggest that zinc oxide nanoparticles (ZnONPs) are useful as antidiabetic agents. However, this evidence was performed and measured in long-term treatments and with repeated doses of ZnONPs. This work aimed to evaluate the ZnONPs acute effects on glycemia during the next six h after an oral or intraperitoneal administration of the treatment in healthy and diabetic rats. In this study, the streptozotocin-nicotinamide intraperitoneal administration in male Wistar rats were used as a diabetes model. 10 mg/kg ZnONPs did not modify the baseline glucose in any group. Nevertheless, the ZnONPs short-term administration (100 mg/kg) induced a hyperglycemic response in a dose and route-dependent administration in healthy (130 ± 2 and 165 ± 10 mg/dL with oral and intraperitoneal, respectively) and diabetic rats (155 ± 2 and 240 ± 20 mg/dL with oral, and intraperitoneal, respectively). The diabetic rats were 1.5 fold more sensitive to ZnONPs effect by the intraperitoneal route. In conclusion, this study provides new information about the acute response of ZnONPs on fasting glycemia in diabetic and healthy rat models; these data are essential for possible future clinical approaches.

Ratas hembras y machos, de tres meses de edad, fueron separados en dos grupos: no diabéticas (ND, peso corporal, 274 ± 9 g; nivel de glucosa en la sangre, 4,94 ± 0,22 mmol/L; n = 16) y diabéticas (D; peso corporal, 207 ± 8 g; nivel de glucosa en sangre, 28,39 ± 0,94 mmol/L; n = 16). La diabetes fue inducida por una sola dosis de 60 mg/Kg de estreptozotocina administrada intraperitonealmente. Las ratas ND recibieron el mismo volumen de vehículo. Después de 4 semanas los animales fueron considerados diabéticos si su nivel de glucosa era ≥ 20 mmol/L. La masa y la contracción del músculo sóleo fueron mayores en machos ND que en las hembras ND. En las ratas macho D disminuyó su masa muscular en un 34% y la fuerza de contracción disminuyó en un 33%; mientras que en las hembras D disminuyeron 15% y 10% respectivamente.

Different studies in experimental diabetes models suggest that zinc oxide nanoparticles (ZnONPs) are useful as antidiabetic agents. However, this evidence was performed and measured in long-term treatments and with repeated doses of ZnONPs. This work aimed to evaluate the ZnONPs acute effects on glycemia during the next six h after an oral or intraperitoneal administration of the treatment in healthy and diabetic rats. In this study, the streptozotocin-nicotinamide intraperitoneal administration in male Wistar rats were used as a diabetes model. 10 mg/kg ZnONPs did not modify the baseline glucose in any group. Nevertheless, the ZnONPs short-term administration (100 mg/kg) induced a hyperglycemic response in a dose and route-dependent administration in healthy (130 ± 2 and 165 ± 10 mg/dL with oral and intraperitoneal, respectively) and diabetic rats (155 ± 2 and 240 ± 20 mg/dL with oral, and intraperitoneal, respectively). The diabetic rats were 1.5 fold more sensitive to ZnONPs effect by the intraperitoneal route. In conclusion, this study provides new information about the acute response of ZnONPs on fasting glycemia in diabetic and healthy rat models; these data are essential for possible future clinical approaches. [ABSTRACT FROM AUTHOR]